

Glucagon (22-29)

Cat. No.:	HY-P3617
CAS No.:	32204-93-6
Molecular Formula:	C ₄₉ H ₇₁ N ₁₁ O ₁₂ S
Molecular Weight:	1038.22
Sequence Shortening:	FVQWLMNT
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Glucagon (22-29) is partial agonist of Glucagon (19-29). Glucagon specifically inhibits the Ca ²⁺ pump in liver plasma membranes independently of adenylate cyclase activation ^{[1][2]} .
In Vitro	Glucagon (22-29) produces only a 5-15% maximal inhibition of (Ca ²⁺ -Mg ²⁺) ATPase, with a low potency (K _i =1 μM), similar to that of native glucagon ^[1] . Glucagon (22-29) (10 nM) evokes an early small decrease of cell contraction when added alone and an 18% significant positive inotropic effect when added in combination with 30 nM glucagon. Glucagon (22-29) thus appears to act as a partial agonist of miniglucagon ^[2] . Glucagon (22-29) consists of the COOH-terminal part of miniglucagon but lacks the three Ala1g-Gln20-Asp21 residues ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Mallat A, et al. A glucagon fragment is responsible for the inhibition of the liver Ca²⁺ pump by glucagon. Nature. 1987 Feb 12-18;325(6105):620-2.

[2]. Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA